TrialCurveChemoradiotherapy ± simultaneous integrated boost in cervical cancer: reconstructed Kaplan–Meier curves
Chemoradiotherapy With or Without Simultaneous Integrated Boost for Cervical Cancer With Full-Thickness Stromal Invasion: A Phase 3 Randomized Clinical Trial. Curves rebuilt as patient-level data (Guyot 2012) and checked against the statistics printed on the figure.
| Publication | JAMA Netw Open. 2025 Sep 19;8(9):e2532501. doi: 10.1001/jamanetworkopen.2025.32501 |
|---|---|
| DOI | 10.1001/jamanetworkopen.2025.32501 |
| Registry | — |
| Phase | — |
| Conditions | — |
| Interventions | — |
| Sponsor | — |
| Enrolment | — |
| Source licence | Figure published under CC BY 4.0 |
Progression-free survival (PFS)
From figure panel A · curves cross-checked by two independent readings · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: SIB radiotherapy not reached; No SIB radiotherapy not reached. Survival at 18 months: SIB radiotherapy 88%; No SIB radiotherapy 83%. Hazard ratio SIB radiotherapy vs No SIB radiotherapy 0.64 (95% CI 0.41–0.98).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| SIB radiotherapy | 233 | 34 | not reached |
| No SIB radiotherapy | 233 | 52 | not reached |
- SIB radiotherapy vs No SIB radiotherapy: reconstructed HR 0.64 (95% CI 0.41–0.98)
Landmark survival (reconstructed)
| Time | SIB radiotherapy | No SIB radiotherapy |
|---|---|---|
| 6 mo | 98.7% | 97.4% |
| 12 mo | 92.7% | 88.8% |
| 18 mo | 88.2% | 82.9% |
| 24 mo | 87.2% | 80.9% |
| 36 mo | 84.8% | 76.9% |
| 48 mo | 83.6% | 70.7% |
Pelvic-specific PFS
From figure panel B · curves cross-checked by two independent readings · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: SIB radiotherapy not reached; No SIB radiotherapy not reached. Survival at 18 months: SIB radiotherapy 96%; No SIB radiotherapy 90%. Hazard ratio SIB radiotherapy vs No SIB radiotherapy 0.43 (95% CI 0.21–0.87).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| SIB radiotherapy | 233 | 11 | not reached |
| No SIB radiotherapy | 233 | 25 | not reached |
- SIB radiotherapy vs No SIB radiotherapy: reconstructed HR 0.43 (95% CI 0.21–0.87)
Landmark survival (reconstructed)
| Time | SIB radiotherapy | No SIB radiotherapy |
|---|---|---|
| 6 mo | 99.6% | 98.7% |
| 12 mo | 96.5% | 93.3% |
| 18 mo | 95.5% | 90.0% |
| 24 mo | 95.5% | 89.4% |
| 36 mo | 94.9% | 88.7% |
| 48 mo | 94.9% | 84.9% |
Overall survival
From figure panel C · curves cross-checked by two independent readings · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: SIB radiotherapy not reached; No SIB radiotherapy not reached. Survival at 18 months: SIB radiotherapy 97%; No SIB radiotherapy 94%. Hazard ratio No SIB radiotherapy vs SIB radiotherapy 1.35 (95% CI 0.76–2.40).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| SIB radiotherapy | 233 | 20 | not reached |
| No SIB radiotherapy | 233 | 27 | not reached |
- No SIB radiotherapy vs SIB radiotherapy: reconstructed HR 1.35 (95% CI 0.76–2.40)
Landmark survival (reconstructed)
| Time | SIB radiotherapy | No SIB radiotherapy |
|---|---|---|
| 6 mo | 99.6% | 99.6% |
| 12 mo | 99.1% | 97.9% |
| 18 mo | 97.4% | 93.8% |
| 24 mo | 95.1% | 90.5% |
| 36 mo | 90.1% | 87.7% |
| 48 mo | 87.2% | 86.3% |
About these data
Pseudo-IPD reproduces the published curves and numbers at risk; the rows are not real patients. Cite the publication (DOI above) and TrialCurve. The source figure is © the authors (CC BY 4.0); the charts here are redrawn from the reconstruction.
Related trials
- PORTEC-3: Overall survival; Recurrence-free survival
- SCORES: Overall survival; Overall survival, final analysis
Need reconstructed data for other trials? Upload any Kaplan–Meier figure, or ask about the TrialCurve oncology library.
Reconstruct a figure Browse all trials